With the Covid-19 outbreak having caused significant disruption to healthcare services, including those for hepatitis C, HCV Action organised a webinar to discuss how services have been affected in different areas across the country and explore how hepatitis C services can most effectively be re-established as we emerge from the early phase of the outbreak. This report provides a summary of the remarks from each of the four speakers and the Q&A which followed.
Access and Uptake of Direct Acting Antiviral Medicines in the UK and selected European countries
Download
This report, produced by IMS Health and commissioned by the Association of the British Pharmaceutical Industry (ABPI), provides information related to the uptake of Direct Acting Antiviral treatments (DAAs) over the last five years, to June 2016. The intention of the report is to benchmark the UK – in relation to patient access to these medicines – compared with other European countries. It finds that there have been significant variances in the ability of patients to access these medicines. For example, Portugal, Belgium and Germany have now treated over a quarter of their estimated prevalent patients. By contrast, the trend in the UK has been one of slower and lower levels of access.
